---
id: 069
title: Flucytosine Mechanism and Clinical Use
category: antimicrobials
subcategory: flucytosine
tags: [flucytosine, 5-FC, cryptococcal-meningitis, amphotericin-B, combination-therapy]
difficulty: medium
---

## Question

What is flucytosine's mechanism and why is it combined with amphotericin B for cryptococcal meningitis? Use the **"5-FU NEVER Alone"** mnemonic.

## Answer

### **"5-FU NEVER Alone" Mnemonic:**

**5-FU:**
- **5**-FC = prodrug (flucytosine)
- **F**ungal enzyme converts to 5-fluorouracil
- **U**racil analog disrupts RNA/DNA

**NEVER Alone:**
- **N**ever monotherapy (rapid resistance)
- **E**nhances ampho B (synergistic)
- **V**ery effective for Cryptococcus
- **E**ssential for induction therapy
- **R**esistance develops in days if alone

**Alone:**
- **A**mpho B + 5-FC = standard induction
- **L**imited spectrum (Cryptococcus, Candida)
- **O**ral formulation available
- **N**arrow therapeutic index (monitor levels)
- **E**arly CSF sterilization

### **Mechanism of Action:**

**Step 1: Selective Uptake**
- Enters fungal cells via **cytosine permease** (selective - humans lack this transporter)

**Step 2: Conversion to Active Form**
- Fungal **cytosine deaminase** converts 5-FC → **5-fluorouracil (5-FU)**
- Humans lack cytosine deaminase → selective toxicity

**Step 3: Dual Inhibition**
- **5-FU** → **5-fluorouridine triphosphate** → **incorporated into RNA** → protein synthesis inhibition
- **5-FU** → **5-fluorodeoxyuridine monophosphate** → inhibits **thymidylate synthase** → DNA synthesis blocked

**Result:** **Fungistatic** effect

### **Spectrum:**

| Organism | Activity | Notes |
|----------|----------|-------|
| ***Cryptococcus neoformans*** | Excellent | **1st-line with ampho B** |
| ***Candida*** spp. | Good | Rarely used (echinoc and azoles better) |
| ***Aspergillus*** | Poor | Not used clinically |
| **Most other fungi** | Poor | Very limited spectrum |

## Key Points

### **Clinical Indications:**

**Primary Use:**
- **Cryptococcal meningoencephalitis induction therapy** (HIV and non-HIV)
  - **Ampho B + 5-FC × 2 weeks** → consolidation with fluconazole

**Combination Regimens:**

| Regimen | Duration | Outcome Benefit |
|---------|----------|-----------------|
| **Ampho B + 5-FC** | 2 weeks induction | **Faster CSF sterilization**, ↓ mortality vs ampho alone |
| Ampho B alone | 2 weeks | Slower clearance, higher mortality |
| **Fluconazole + 5-FC** | Alternative if ampho contraindicated | Less effective than ampho + 5-FC |

**Evidence:** Combination therapy with 5-FC results in **more rapid CSF sterilization** and **improved mortality** vs amphotericin alone

### **Dosing:**

**Standard Dose:**
- **100 mg/kg/day PO divided q6h** (25 mg/kg QID)
- **Adjust for renal impairment** (renally cleared)

**Renal Dosing:**

| CrCl (mL/min) | Dose Adjustment |
|---------------|-----------------|
| **>50** | 100 mg/kg/day q6h |
| **20-50** | 50 mg/kg q12h |
| **10-20** | 50 mg/kg q24h |
| **<10 or HD** | 50 mg/kg after dialysis |

### **Why Combination Therapy Essential:**

1. **Synergy with ampho B:** Enhanced fungal killing
2. **Prevents resistance:** Rapid resistance if monotherapy (days)
3. **Faster CSF sterilization:** 2× faster than ampho alone
4. **Improved mortality:** Reduced death rates in cryptococcal meningitis

### **Clinical Pearls:**
- **NEVER use as monotherapy** (resistance develops within days)
- **Oral bioavailability >90%** (can use PO formulation)
- **Synergistic with ampho B** for Cryptococcus
- **Gold standard induction** for cryptococcal meningitis: Ampho B + 5-FC × 14 days
- **Limited availability** globally (access issue in many countries)
- Monitor levels if available (target: 30-80 µg/mL)

## Sources

- [StatPearls NBK557607: Flucytosine 2024]
- [PMC3797641: Flucytosine and Cryptococcosis Accessibility]
- [AAC 2007: Oral vs IV Flucytosine in Cryptococcal Meningitis]

## Media

N/A
